Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 116Active not recruiting 19Terminated 18Recruiting 17Unknown 14Withdrawn 6Not yet recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 2Interventional 2

Sponsor

Cancer Type

Head & Neck 2Thoracic 1Gynecologic 1Gastrointestinal 1

Conditions

Breast Neoplasms 424Neoplasms 281Carcinoma, Non-Small-Cell Lung 272Colorectal Neoplasms 236Prostatic Neoplasms 173Lung Neoplasms 172Carcinoma, Hepatocellular 157Stomach Neoplasms 126Leukemia, Myeloid, Acute 120Pancreatic Neoplasms 118Multiple Myeloma 106Recurrence 99Uterine Cervical Neoplasms 97Squamous Cell Carcinoma of Head and Neck 89Neoplasm Metastasis 88Rectal Neoplasms 87Ovarian Neoplasms 81Triple Negative Breast Neoplasms 77Small Cell Lung Carcinoma 72Head and Neck Neoplasms 69Brain Neoplasms 68Esophageal Neoplasms 65Glioblastoma 64Endometrial Neoplasms 60Colonic Neoplasms 59Melanoma 55Hematologic Neoplasms 53Precursor Cell Lymphoblastic Leukemia-Lymphoma 48Motor Activity 48Carcinoma, Renal Cell 47

Interventions

neratinib 1RC48 antibody 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Interventional × Salivary Gland Neoplasms × Clear all
NCT06519110 2024-07-25

CVL009-C2001

Convalife (Shanghai) Co., Ltd.

Phase 2 Not yet recruiting
60 enrolled
GastrointestinalGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Salivary Gland Neoplasms, Cholangiocarcinoma

NCT05898373 2023-06-12

Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC

Peking Union Medical College

Phase 1/2 Not yet recruiting
120 enrolled
Head & Neck

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡